Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CDC25A | P30304 | 2/20 | 0.31 |
| ▸ | CDC25B | P30305 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501741 | 0.92 | MAPT (0.49) | MAPTGBA1PTPN1LMNACDC25A | |
| SCHEMBL876348 | 0.89 | — | — | |
| SCHEMBL21633983 | 0.86 | GBA1 (0.33) | MAPTGBA1ESR1CYP3A4CYP2C9 | |
| SCHEMBL13976304 | 0.84 | LMNA (0.46) | MAPTGBA1PTPN1LMNACDC25A | |
| SCHEMBL6570906 | 0.83 | MAPT (0.42) | MAPTGBA1CYP1A2LMNAMAPK1 | |
| SCHEMBL12981938 | 0.79 | CYP1A2 (0.46) | MAPTCYP1A2LMNA | |
| SCHEMBL28414746 | 0.79 | LMNA (0.42) | MAPTGBA1CYP1A2LMNAMAPK1 | |
| SCHEMBL9379793 | 0.79 | CYP1A2 (0.52) | MAPTCYP1A2LMNA | |
| SCHEMBL17592418 | 0.78 | MAPT (0.39) | MAPTCYP1A2LMNAMAPK1HTT | |
| SCHEMBL17592347 | 0.78 | MAPT (0.39) | MAPTCYP1A2LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634659-B2 | Fragrances with rose scent | SYMRISE AG (DE) | 2023-04-25 | — | — | US | disclosed |
| US-20210324300-A1 | NOVEL FRAGRANCES WITH ROSE SCENT | SYMRISE AG (DE) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634659-B2 | Fragrances with rose scent | NR1H2, DUOX2, AOX1 | MAPT 1597/4885GBA1 4704/4885PTPN1 4029/4885 |
| US-20210324300-A1 | NOVEL FRAGRANCES WITH ROSE SCENT | NR1H2, DUOX2, AOX1 | MAPT 1898/4885GBA1 4716/4885PTPN1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.